Maryam B. Lustberg
Ohio State University
272 Papers
452 Citations
Maryam B. Lustberg is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 31, co-authored 190 publications. Previous affiliations of Maryam B. Lustberg include James Cancer Hospital & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Chat about Author
Papers
Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer
Robert Wesolowski,Daniel G. Stover,Maryam B. Lustberg,Abigail B. Shoben,Meng Zhao,Ewa Mrozek,Rachel M. Layman,Erin Macrae,Wenrui Duan,Jun Zhang,Nathan Hall,Chadwick Wright,Katharina Schregel,Susan Gillespie,Michael Berger,Andrea Camp,Jeffrey J. Chalmers,Priya Balasubramanian,Brandon Miller,Peter Amaya,Eleni Andreopoulou,Joseph A. Sparano,Charles L. Shapiro,Miguel A. Villalona-Calero,Susan Geyer,Alice P. Chen,Michael R. Grever,Michael V. Knopp,Bhuvaneswari Ramaswamy +28 more
TL;DR: Continuous dosing of veliparib and every three week carboplatin demonstrated activity and acceptable toxicity and decrease in SUVmax on 18FLT-PET scan during the first cycle of this therapy can identify patients likely to have a response.
CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer
Dionisia Quiroga,Ashley Pinette,Brooke Benner,E. Schwarz,Robert Wesolowski,Andrew Stiff,Sara Zelinskas,Erin Macrae,Maryam B. Lustberg,Ewa Mrozek,Bhuvaneswari Ramaswamy,William E. Carson +11 more
TL;DR: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination with Trastuzumab in Patients With Metastatic Breast Cancer as mentioned in this paper .
Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck
Priya Balasubramanian,James C. Lang,Kris R. Jatana,Kris R. Jatana,Brandon Miller,Enver Ozer,M. Old,David E. Schuller,Amit Agrawal,Theodoros N. Teknos,Thomas A. Summers,Maryam B. Lustberg,Maciej Zborowski,Jeffrey J. Chalmers +13 more
TL;DR: It is suggested that the negative depletion enrichment methodology provides a more objective approach in identifying and evaluating CTCs, as opposed to positive selection approaches, as it is not subjective to a selection bias and can be tailored to accommodate a variety of cytoplasmic and surface markers.
Risk factors for anthracycline-associated cardiotoxicity
Raquel E. Reinbolt,Roshan Patel,Xueliang Pan,Cynthia Timmers,Robert Pilarski,Charles L. Shapiro,Maryam B. Lustberg +6 more
TL;DR: This is the first study to evaluate SNPs in the CBR pathway as predictors of AC cardiotoxicity in adults and did not observe any significant correlation between cardiot toxicity and SNPs within theCBR pathway.
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Mellissa Hicks,Erin Macrae,Mahmoud Abdel-Rasoul,Rachel M. Layman,Susan Friedman,Jenny Querry,Maryam B. Lustberg,Bhuvaneswari Ramaswamy,Ewa Mrozek,Charles L. Shapiro,Robert Wesolowski +10 more
TL;DR: The addition of lapatinib to trastuzumab in combination with neoadjuvant chemotherapy significantly improves pCR rates in patients with HER2-positive breast cancer.